Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Core Viewpoint - Evofem Biosciences, Inc. anticipates the approval of a merger with Aditxt, Inc. and its subsidiary Adifem, which is set to be voted on at a Special Meeting of Stockholders on September 26, 2025 [1][2]. Summary by Sections Merger Details - The merger involves Adifem merging with Evofem, with Evofem becoming a wholly owned subsidiary of Aditxt, aimed at enhancing women's health initiatives [2][7]. - The proposal requires approval from at least a majority of the combined voting power of common stock, Series E-1, and G-1 [2][8]. Stockholder Support - CEO Saundra Pelletier indicated that support agreements are in place with holders of Series E-1 and G-1, which collectively represent 53.71% of the combined voting power [2][3]. - The holders of Series E-1 and G-1 have 13.87% and 39.84% of the voting power, respectively [3]. Company Mission and Products - Evofem is focused on delivering innovations in sexual and reproductive healthcare, with two FDA-approved products generating revenue: PHEXXI and SOLOSEC [4][5][6]. - PHEXXI is a hormone-free contraceptive vaginal gel, while SOLOSEC is an oral antibiotic for treating bacterial vaginosis and trichomoniasis [5][6].